Which has higher earnings & valuation, GUTS or KMDA?

Kamada has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fractyl Health N/A N/A -$140.95M -$0.88 N/A Kamada $180.46M 2.42 $20.20M $0.35 21.66

Is GUTS or KMDA more profitable?

Kamada has a net margin of 11.60% compared to Fractyl Health's net margin of 0.00%. Kamada's return on equity of 8.37% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Kamada 11.60% 8.37% 5.85%

Does the media refer more to GUTS or KMDA?

In the previous week, Fractyl Health had 4 more articles in the media than Kamada. MarketBeat recorded 19 mentions for Fractyl Health and 15 mentions for Kamada. Fractyl Health's average media sentiment score of 0.88 beat Kamada's score of 0.56 indicating that Fractyl Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 3 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GUTS or EDIT?

In the previous week, Fractyl Health had 5 more articles in the media than Editas Medicine. MarketBeat recorded 19 mentions for Fractyl Health and 14 mentions for Editas Medicine. Fractyl Health's average media sentiment score of 0.88 beat Editas Medicine's score of 0.88 indicating that Fractyl Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GUTS or ELYM?

Fractyl Health presently has a consensus target price of $5.12, suggesting a potential upside of 652.94%. Given Fractyl Health's stronger consensus rating and higher probable upside, research analysts plainly believe Fractyl Health is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fractyl Health 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, GUTS or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fractyl Health N/A N/A -$140.95M -$0.88 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is GUTS or ELYM more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Eliem Therapeutics N/A -47.03% -45.97%

Which has preferable valuation & earnings, EPRX or GUTS?

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A Fractyl Health N/A N/A -$140.95M -$0.88 N/A

Is EPRX or GUTS more profitable?

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -63.97% -43.32% Fractyl Health N/A -1,362.10% -84.89%

Does the media prefer EPRX or GUTS?

In the previous week, Fractyl Health had 8 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 19 mentions for Fractyl Health and 11 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.92 beat Fractyl Health's score of 0.88 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fractyl Health 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, BNTC or GUTS?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$37.92M -$1.14 N/A Fractyl Health N/A N/A -$140.95M -$0.88 N/A

Is BNTC or GUTS more profitable?

Benitec Biopharma's return on equity of -34.82% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -34.82% -34.11% Fractyl Health N/A -1,362.10% -84.89%

Does the media refer more to BNTC or GUTS?

In the previous week, Fractyl Health had 16 more articles in the media than Benitec Biopharma. MarketBeat recorded 19 mentions for Fractyl Health and 3 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.00 beat Fractyl Health's score of 0.88 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fractyl Health 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fractyl Health (GUTS) Competitors

$0.68 +0.02 (+2.72%)

Closing price 04:00 PM Eastern

Extended Trading

$0.68 0.00 (-0.29%)

As of 07:59 PM Eastern

Compare

GUTS vs. KMDA, EDIT, ELYM, EPRX, and BNTC

Should you buy Fractyl Health stock or one of its competitors? Fractyl Health's main competitors and comparable companies include Kamada (KMDA), Editas Medicine (EDIT), Eliem Therapeutics (ELYM), Eupraxia Pharmaceuticals (EPRX), and Benitec Biopharma (BNTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fractyl Health compare to Kamada?

Fractyl Health (NASDAQ:GUTS) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

20.4% of Kamada shares are owned by institutional investors. 8.5% of Fractyl Health shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kamada has a net margin of 11.60% compared to Fractyl Health's net margin of 0.00%. Kamada's return on equity of 8.37% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Kamada	11.60%	8.37%	5.85%

Fractyl Health currently has a consensus target price of $5.12, indicating a potential upside of 652.94%. Kamada has a consensus target price of $13.00, indicating a potential upside of 71.50%. Given Fractyl Health's higher probable upside, research analysts clearly believe Fractyl Health is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	N/A	N/A	-$140.95M	-$0.88	N/A
Kamada	$180.46M	2.42	$20.20M	$0.35	21.66

Fractyl Health has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market. Comparatively, Kamada has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

In the previous week, Fractyl Health had 4 more articles in the media than Kamada. MarketBeat recorded 19 mentions for Fractyl Health and 15 mentions for Kamada. Fractyl Health's average media sentiment score of 0.88 beat Kamada's score of 0.56 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kamada beats Fractyl Health on 10 of the 15 factors compared between the two stocks.

How does Fractyl Health compare to Editas Medicine?

Fractyl Health (NASDAQ:GUTS) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

In the previous week, Fractyl Health had 5 more articles in the media than Editas Medicine. MarketBeat recorded 19 mentions for Fractyl Health and 14 mentions for Editas Medicine. Fractyl Health's average media sentiment score of 0.88 beat Editas Medicine's score of 0.88 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.9% of Editas Medicine shares are owned by institutional investors. 8.5% of Fractyl Health shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Fractyl Health currently has a consensus target price of $5.12, suggesting a potential upside of 652.94%. Editas Medicine has a consensus target price of $5.40, suggesting a potential upside of 91.49%. Given Fractyl Health's higher probable upside, equities research analysts clearly believe Fractyl Health is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Fractyl Health has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. Editas Medicine's return on equity of -196.63% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Editas Medicine	-157.32%	-196.63%	-38.17%

Fractyl Health has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Fractyl Health has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	N/A	N/A	-$140.95M	-$0.88	N/A
Editas Medicine	$40.52M	10.69	-$160.06M	-$0.75	N/A

Summary

Fractyl Health beats Editas Medicine on 8 of the 13 factors compared between the two stocks.

How does Fractyl Health compare to Eliem Therapeutics?

Fractyl Health (NASDAQ:GUTS) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, Fractyl Health had 19 more articles in the media than Eliem Therapeutics. MarketBeat recorded 19 mentions for Fractyl Health and 0 mentions for Eliem Therapeutics. Fractyl Health's average media sentiment score of 0.88 beat Eliem Therapeutics' score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Overall Sentiment
Fractyl Health	Positive
Eliem Therapeutics	Neutral

69.8% of Eliem Therapeutics shares are owned by institutional investors. 8.5% of Fractyl Health shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	N/A	N/A	-$140.95M	-$0.88	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Eliem Therapeutics' return on equity of -47.03% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Fractyl Health has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Fractyl Health presently has a consensus target price of $5.12, suggesting a potential upside of 652.94%. Given Fractyl Health's stronger consensus rating and higher probable upside, research analysts plainly believe Fractyl Health is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Fractyl Health beats Eliem Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Fractyl Health compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Fractyl Health	N/A	-1,362.10%	-84.89%

Eupraxia Pharmaceuticals currently has a consensus price target of $18.00, suggesting a potential upside of 167.86%. Fractyl Health has a consensus price target of $5.12, suggesting a potential upside of 652.94%. Given Fractyl Health's higher probable upside, analysts clearly believe Fractyl Health is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Fractyl Health had 8 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 19 mentions for Fractyl Health and 11 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.92 beat Fractyl Health's score of 0.88 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fractyl Health	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market.

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Fractyl Health	N/A	N/A	-$140.95M	-$0.88	N/A

Summary

Eupraxia Pharmaceuticals beats Fractyl Health on 7 of the 11 factors compared between the two stocks.

How does Fractyl Health compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Fractyl Health (NASDAQ:GUTS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Benitec Biopharma's return on equity of -34.82% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
Fractyl Health	N/A	-1,362.10%	-84.89%

52.2% of Benitec Biopharma shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by insiders. Comparatively, 8.5% of Fractyl Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Benitec Biopharma has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market.

Benitec Biopharma is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A
Fractyl Health	N/A	N/A	-$140.95M	-$0.88	N/A

In the previous week, Fractyl Health had 16 more articles in the media than Benitec Biopharma. MarketBeat recorded 19 mentions for Fractyl Health and 3 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.00 beat Fractyl Health's score of 0.88 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fractyl Health	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Benitec Biopharma currently has a consensus target price of $24.80, indicating a potential upside of 97.45%. Fractyl Health has a consensus target price of $5.12, indicating a potential upside of 652.94%. Given Fractyl Health's higher probable upside, analysts clearly believe Fractyl Health is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Benitec Biopharma beats Fractyl Health on 7 of the 13 factors compared between the two stocks.

Get Fractyl Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUTS vs. The Competition

Export

Metric	Fractyl Health	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$105.38M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.77	6.29	211.09	21.74
Price / Sales	N/A	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-68.00	16.78	12.91	6.24
Net Income	-$140.95M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-2.80%	1.74%	1.12%	1.07%
1 Month Performance	-15.00%	1.60%	1.79%	1.03%
1 Year Performance	-30.43%	56.43%	67.69%	20.77%

Fractyl Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUTS Fractyl Health	3.9499 of 5 stars	$0.68 +2.7%	$5.12 +652.9%	-34.5%	$105.38M	N/A	N/A	102	News Coverage Earnings Report Analyst Revision Gap Up
KMDA Kamada	4.9332 of 5 stars	$7.54 +3.9%	$13.00 +72.4%	-1.6%	$433.63M	$180.46M	19.84	360	News Coverage Earnings Report Analyst Revision High Trading Volume
EDIT Editas Medicine	2.3804 of 5 stars	$2.80 -0.5%	$5.40 +93.2%	-8.8%	$429.26M	$40.52M	N/A	230	Analyst Upgrade
ELYM Eliem Therapeutics	N/A	$14.39 +3.9%	N/A	+793.8%	$428.13M	N/A	N/A	9	High Trading Volume
EPRX Eupraxia Pharmaceuticals	2.4232 of 5 stars	$6.58 -1.3%	$18.00 +173.6%	+22.4%	$427.83M	N/A	N/A	29	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GUTS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fractyl Health (GUTS) Competitors

GUTS vs. KMDA, EDIT, ELYM, EPRX, and BNTC

How does Fractyl Health compare to Kamada?

Summary

How does Fractyl Health compare to Editas Medicine?

Summary

How does Fractyl Health compare to Eliem Therapeutics?

Summary

How does Fractyl Health compare to Eupraxia Pharmaceuticals?

Summary

How does Fractyl Health compare to Benitec Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fractyl Health (GUTS) Competitors

GUTS vs. KMDA, EDIT, ELYM, EPRX, and BNTC

How does Fractyl Health compare to Kamada?

Do insiders & institutionals hold more shares of GUTS or KMDA?

Is GUTS or KMDA more profitable?

Do analysts rate GUTS or KMDA?

Which has higher earnings & valuation, GUTS or KMDA?

Which has more volatility & risk, GUTS or KMDA?

Does the media refer more to GUTS or KMDA?

Summary

How does Fractyl Health compare to Editas Medicine?

Does the media favor GUTS or EDIT?

Do institutionals & insiders hold more shares of GUTS or EDIT?

Do analysts rate GUTS or EDIT?

Is GUTS or EDIT more profitable?

Which has more volatility & risk, GUTS or EDIT?

Which has preferable valuation & earnings, GUTS or EDIT?

Summary

How does Fractyl Health compare to Eliem Therapeutics?

Does the media refer more to GUTS or ELYM?

Do insiders and institutionals hold more shares of GUTS or ELYM?

Which has better earnings & valuation, GUTS or ELYM?

Is GUTS or ELYM more profitable?

Which has more risk & volatility, GUTS or ELYM?

Do analysts rate GUTS or ELYM?

Summary

How does Fractyl Health compare to Eupraxia Pharmaceuticals?

Is EPRX or GUTS more profitable?

Do analysts rate EPRX or GUTS?

Does the media prefer EPRX or GUTS?

Which has more risk & volatility, EPRX or GUTS?

Which has preferable valuation & earnings, EPRX or GUTS?

Summary

How does Fractyl Health compare to Benitec Biopharma?

Is BNTC or GUTS more profitable?

Do insiders and institutionals believe in BNTC or GUTS?

Which has more volatility and risk, BNTC or GUTS?

Which has stronger earnings & valuation, BNTC or GUTS?

Does the media refer more to BNTC or GUTS?

Do analysts recommend BNTC or GUTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools